Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. - sprookjes - yvandenbroek - TriplyDB

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q34293726

about

Targeted therapy for advanced renal cell carcinoma mTOR inhibitors in advanced renal cell carcinoma Bone Metastasis from Renal Cell Carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)Cytoreductive surgery in the era of targeted molecular therapy Sunitinib in the treatment of metastatic renal cell carcinoma Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib Renal cell cancer: overview of the current therapeutic landscape.The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea Sunitinib in metastatic renal cell carcinoma patients with brain metastases.Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.Evaluation of everolimus in renal cell cancer.Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Assessment of efficacy, safety and quality of life of 55 patients with metastatic renal cell carcinoma treated with temsirolimus: a single-center experience in Japan.Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.Nasal metastases from renal cell carcinoma are associated with Memorial Sloan-Kettering Cancer Center poor-prognosis classification.Staging of renal cell carcinoma: Current concepts.Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience.Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma.Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course

P2860

Q24242946-DEA2F67D-3DA6-463B-B485-014B95C54976 Q24612127-628AC1B7-9CC5-4FC3-A5EB-5D8E9D88A77A Q26747493-BA8AC060-3E9D-40B1-86AC-FA73E4216BE7 Q26772206-E530F933-9699-432A-9DB7-245FB23CAD6D Q26774134-192F956E-BBF2-4819-AA3A-B5BB0DF2C27E Q28072057-B2E4C701-12D1-484D-9222-42A04756E6F5 Q28079861-B24D7F4B-6261-466A-9BB7-9E80E61580E6 Q28765488-EE81A4FB-BFF7-4E32-A416-9707C0AB1673 Q30248354-ADCD2900-4D5A-4480-8900-B1765B3C7502 Q30250343-FA6FA269-93EC-4233-A9E8-2372D5A7DB77 Q30486440-036062A4-8608-456A-BD8C-392975255C3E Q33380414-7E2FCA2B-CC0F-4070-A2B3-6B270260F09A Q33384592-348DB204-836C-4933-B5CE-79F177676A61 Q33385981-CE703059-8D80-494B-A859-CA685ACD0842 Q33391978-59EF5C61-1022-4AF5-9E0F-C1F00FFE9A04 Q33396136-BA81713C-317D-4ED8-94C9-1AD53F7851B4 Q33396613-7E48A401-E927-4159-ADA0-A2204DB7A530 Q33396965-38E6E0BB-F1A5-4D95-A137-313F331999B9 Q33407015-2813B280-6C4F-41E3-BBCF-169C86A23D07 Q33408085-F36AFB81-8736-4402-897D-8DA4FF4EFCBA Q33410206-26A77CDC-26CC-4096-943C-35D49525DBB8 Q33410223-9E771380-3EF7-4B52-86B6-50650EA3A13F Q33434845-4A015DDC-3F4C-41C1-B381-9865D2FFC425 Q33579457-715E5612-8C5D-4794-8DEA-DB44F5AACD7C Q33599726-A37C42BF-EF75-4FD6-B769-A3795226BD5F Q33606102-EEF0B663-058D-4516-9ECE-3BEC0FAE47E9 Q33710169-C1CAB85E-42DE-4681-AE2F-62D5AF04BDA0 Q33843677-13BE8816-81F2-4F2C-A6B6-598EBE491809 Q33881423-9EDE5ABE-9E2F-4995-B1C6-6AF479C8B58B Q33883229-7A1552B5-59C4-4B6A-8D28-9895083F5A23 Q33887804-7C20588E-9495-468E-A079-19BB6DDB5B23 Q34009449-37FF0F13-0EF8-4C21-8439-D21710C2D85D Q34021843-B8160EF5-55D5-42C4-AFCA-CA457B73515E Q34023737-C5C73B2C-F47A-4F55-991F-20A461AD1E50 Q34081653-EFB74176-A58A-4653-AA9C-952ADA3B4C25 Q34086952-B48231AA-FE0B-40F9-87CA-12A9C8615C6F Q34105997-64D4A1C4-59D8-4200-9483-5DEFEEFF95C7 Q34206601-A4612ADD-F6D6-40BC-8A01-B92B99665E84 Q34245458-41F496BE-53A7-4AC1-802E-B639F85F8A5A Q34253776-3C10AA17-A023-4EF5-846A-B588352C9D0B

P2860

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

http://www.wikidata.org/entity/Q34293726

description

2004 nî lūn-bûn

@nan

2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@ast

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@en

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@nl

type

label

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@ast

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@en

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@nl

prefLabel

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@ast

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@en

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@nl

P1433

Q34293726-ADBB0238-CE52-4252-9A28-6E3FFA4EA623

P1476

Q34293726-6FC4218D-2CD2-41B3-A444-CAE8D38A03C5

P2093

Q34293726-3802F50C-0A1E-45CD-B04B-9EE09FA7481F

Q34293726-8E4C42EE-38CC-4B44-A5FA-CE79D5C2031E

Q34293726-8F751154-017E-402D-BC96-5F50D8E078CD

Q34293726-B811D832-D0D1-470F-8C86-2912FBE10663

Q34293726-F33276C5-E509-4A7C-8B15-E9E13DAA4A2C

Q34293726-F6B28EC7-6713-4C24-9053-81C13C6C7E4D

P304

Q34293726-C9AD7082-0134-489E-8A36-0A6682769D72

P31

Q34293726-6B6C0E5E-FE37-46AB-8C84-C7DA38760475

P356

Q34293726-59343B29-67EF-465C-9FD7-EF77B1EDC9C9

P407

Q34293726-171A0D95-D436-4EFC-842D-B092A1A8EBDF

P433

Q34293726-0F889405-3401-498B-AE11-EA4DE3EBAAFB

P478

Q34293726-2C1E172B-7111-4CB8-8229-D0AE3EA35ED3

P50

Q34293726-0AEF30B4-A636-4DCF-BA94-C8BD53CBC5C9

P577

Q34293726-6491B695-0B2A-4454-82AC-587DA66EE857

P698

Q34293726-055B07D9-513B-4C0C-ADF1-DE3BF0DCB2E9

P921

Q34293726-6E742951-749A-4EBF-A389-3360AFC8FA08

P356

JCO.2004.06.132

P1433

Journal of Clinical Oncology

P1476

Prognostic factors for surviva ...... tastatic renal cell carcinoma.

@en

P2093

Jennifer Bacik

http://www.w3.org/2001/XMLSchema#string

Lawrence H Schwartz

http://www.w3.org/2001/XMLSchema#string

Madhu Mazumdar

http://www.w3.org/2001/XMLSchema#string

Paul Russo

http://www.w3.org/2001/XMLSchema#string

Stephanie Marion

http://www.w3.org/2001/XMLSchema#string

Victor Reuter

http://www.w3.org/2001/XMLSchema#string

P304

454-463

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.06.132

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14752067

http://www.w3.org/2001/XMLSchema#string

P921